Search

Your search keyword '"Gayoso, Regina"' showing total 16 results
Start Over Author "Gayoso, Regina"
16 results on '"Gayoso, Regina"'

1. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

treatment–2017, The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB, Ahmad, Nafees, Ahuja, Shama D, Akkerman, Onno W, Alffenaar, Jan-Willem C, Anderson, Laura F, Baghaei, Parvaneh, Bang, Didi, Barry, Pennan M, Bastos, Mayara L, Behera, Digamber, Benedetti, Andrea, Bisson, Gregory P, Boeree, Martin J, Bonnet, Maryline, Brode, Sarah K, Brust, James CM, Cai, Ying, Caumes, Eric, Cegielski, J Peter, Centis, Rosella, Chan, Pei-Chun, Chan, Edward D, Chang, Kwok-Chiu, Charles, Macarthur, Cirule, Andra, Dalcolmo, Margareth Pretti, D'Ambrosio, Lia, de Vries, Gerard, Dheda, Keertan, Esmail, Aliasgar, Flood, Jennifer, Fox, Gregory J, Fréchet-Jachym, Mathilde, Fregona, Geisa, Gayoso, Regina, Gegia, Medea, Gler, Maria Tarcela, Gu, Sue, Guglielmetti, Lorenzo, Holtz, Timothy H, Hughes, Jennifer, Isaakidis, Petros, Jarlsberg, Leah, Kempker, Russell R, Keshavjee, Salmaan, Khan, Faiz Ahmad, Kipiani, Maia, Koenig, Serena P, Koh, Won-Jung, Kritski, Afranio, Kuksa, Liga, Kvasnovsky, Charlotte L, Kwak, Nakwon, Lan, Zhiyi, Lange, Christoph, Laniado-Laborín, Rafael, Lee, Myungsun, Leimane, Vaira, Leung, Chi-Chiu, Leung, Eric Chung-Ching, Li, Pei Zhi, Lowenthal, Phil, Maciel, Ethel L, Marks, Suzanne M, Mase, Sundari, Mbuagbaw, Lawrence, Migliori, Giovanni B, Milanov, Vladimir, Miller, Ann C, Mitnick, Carole D, Modongo, Chawangwa, Mohr, Erika, Monedero, Ignacio, Nahid, Payam, Ndjeka, Norbert, O'Donnell, Max R, Padayatchi, Nesri, Palmero, Domingo, Pape, Jean William, Podewils, Laura J, Reynolds, Ian, Riekstina, Vija, Robert, Jérôme, Rodriguez, Maria, Seaworth, Barbara, Seung, Kwonjune J, Schnippel, Kathryn, Shim, Tae Sun, Singla, Rupak, Smith, Sarah E, Sotgiu, Giovanni, Sukhbaatar, Ganzaya, Tabarsi, Payam, Tiberi, Simon, Trajman, Anete, Trieu, Lisa, Udwadia, Zarir F, van der Werf, Tjip S, and Veziris, Nicolas

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Tuberculosis, Lung, Antimicrobial Resistance, Prevention, Clinical Trials and Supportive Activities, Rare Diseases, Orphan Drug, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Amikacin, Antitubercular Agents, Capreomycin, Carbapenems, Clofazimine, Diarylquinolines, Drug Therapy, Combination, Fluoroquinolones, Humans, Kanamycin, Levofloxacin, Linezolid, Moxifloxacin, Recurrence, Treatment Failure, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTreatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis.MethodsIn this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016. We also searched reference lists from all systematic reviews of treatment of multidrug-resistant tuberculosis published since 2009. To be eligible, studies had to report original results, with end of treatment outcomes (treatment completion [success], failure, or relapse) in cohorts of at least 25 adults (aged >18 years). We used anonymised individual patient data from eligible studies, provided by study investigators, regarding clinical characteristics, treatment, and outcomes. Using propensity score-matched generalised mixed effects logistic, or linear regression, we calculated adjusted odds ratios and adjusted risk differences for success or death during treatment, for specific drugs currently used to treat multidrug-resistant tuberculosis, as well as the number of drugs used and treatment duration.FindingsOf 12 030 patients from 25 countries in 50 studies, 7346 (61%) had treatment success, 1017 (8%) had failure or relapse, and 1729 (14%) died. Compared with failure or relapse, treatment success was positively associated with the use of linezolid (adjusted risk difference 0·15, 95% CI 0·11 to 0·18), levofloxacin (0·15, 0·13 to 0·18), carbapenems (0·14, 0·06 to 0·21), moxifloxacin (0·11, 0·08 to 0·14), bedaquiline (0·10, 0·05 to 0·14), and clofazimine (0·06, 0·01 to 0·10). There was a significant association between reduced mortality and use of linezolid (-0·20, -0·23 to -0·16), levofloxacin (-0·06, -0·09 to -0·04), moxifloxacin (-0·07, -0·10 to -0·04), or bedaquiline (-0·14, -0·19 to -0·10). Compared with regimens without any injectable drug, amikacin provided modest benefits, but kanamycin and capreomycin were associated with worse outcomes. The remaining drugs were associated with slight or no improvements in outcomes. Treatment outcomes were significantly worse for most drugs if they were used despite in-vitro resistance. The optimal number of effective drugs seemed to be five in the initial phase, and four in the continuation phase. In these adjusted analyses, heterogeneity, based on a simulated I2 method, was high for approximately half the estimates for specific drugs, although relatively low for number of drugs and durations analyses.InterpretationAlthough inferences are limited by the observational nature of these data, treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis. These findings emphasise the need for trials to ascertain the optimal combination and duration of these drugs for treatment of this condition.FundingAmerican Thoracic Society, Canadian Institutes of Health Research, US Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America.

Published
2018

3. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Author

Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, Migliori, Giovanni Battista, Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, and Migliori, Giovanni Battista

Published
2021

4. Características clínicas e epidemiológicas de casos de infecção pulmonar por Mycobacterium kansasii no Rio de Janeiro, no período de 2006 a 2016

Author

Goldenberg,Telma, Gayoso,Regina, Mogami,Roberto, Lourenço,Maria Cristina, Ramos,Jesus Paes, Carvalho,Luciana Distasio de, Dalcolmo,Margareth Pretti, and Mello,Fernanda Carvalho de Queiroz

Subjects
Treatment, Diseases of the respiratory system, Tratamento, RC705-779, Micobactéria não tuberculosa, Epidemiology, Mycobacterium kansasii, Epidemiologia, Nontuberculous mycobacteria
Abstract

RESUMO Objetivo Avaliar características clínicas, tomográficas e microbiológicas dos pacientes com doença pulmonar causada pela M. kansasii (DPMK) atendidos em unidade ambulatorial no período 2006-2016. Métodos Estudo descritivo, em que foram analisados 38 pacientes. Foram analisadas as características demográficas, clínico-radiológicas, laboratoriais e terapêuticas. Resultados A média de idade foi 64 anos (DP=10,6; IIQ=57-72; mediana=65,0) e 22 (57,9%) eram pacientes do sexo masculino. Comorbidade pulmonar estava presente em 89,5%. A comorbidade mais frequente foi a bronquiectasia (78,9%). Tratamento anterior para tuberculose pulmonar (TBP) foi relatado em 65,9%. O esquema terapêutico mais utilizado foi rifampicina, isoniazida e etambutol (44,7%). A tomografia de tórax (TCT) mostrou bronquiectasia (94,1%), distorção arquitetural (76,5%), espessamento de septo (67,6%) e cavidades (64,7%). A doença foi bilateral em 85,2%. Houve 10,7% de resistência à rifampicina, 67,9% resistentes ao etambutol e sensibilidade à claritromicina. Conclusão Em pacientes com doença pulmonar estrutural, é importante a busca de DPMNT, principal diagnóstico diferencial com TBP. TC de tórax demonstra diferentes padrões que se sobrepõem ao de doença estrutural causada por TBP ou outras enfermidades pulmonares. Destaca-se a resistência ao etambutol, fármaco componente do esquema preconizado. ABSTRACT Objective To evaluate clinical, tomographic, and microbiological characteristics of pulmonary disease caused by M. kansasii (MKPD) in patients treated at an outpatient unit from 2006-2016. Methods We studied thirty eight patients, and analyzed socio-demographic, clinical-radiological, laboratory, and therapeutic characteristics. Results The mean age was 64 years (SD = 10.6; IIQ = 57-72; median = 65.0), and 22 (57.9%) male patients. Pulmonary comorbidity was present in 89.5% of the patients. The most frequent comorbidity was bronchiectasis (78.9%). Previous treatment for pulmonary tuberculosis (PTB) was found in 65.9%. The most used therapeutic regimen was rifampicin, isoniazid and ethambutol (44.7%). Chest tomography (CT) showed bronchiectasis (94.1%), architectural distortion (76.5%), septum thickening (67.6%), and cavities (64.7%). Disease was bilateral in 85.2%. We observed 10.7% resistance to rifampicin, 67.9% resistance to ethambutol, and sensitivity to clarithromycin. Conclusion In patients with structural lung disease, it is important to search for NTM, the main differential diagnosis with PTB. Chest CT showed different patterns that overlapped with structural disease caused by PTB or other lung diseases. We observed resistance to ethambutol, a drug component of the recommended regimen.

Published
2020

5. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

Author

Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan-Willem, Al-Marzouqi, Nada Hassan, Arias-Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey E., Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García-García, José-María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska-Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado-Laborín, Rafael, Li, Yang, Magis-Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Munoz-Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie-Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendon, Adrian, Skrahina, Alena, Šmite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, and Zignol, Matteo

Published
2019
Full Text
View/download PDF

7. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis

Author

Kwak, Nakwon, Dalcolmo, Margareth Pretti, Daley, Charles L., Eather, Geoffrey, Gayoso, Regina, Hasegawa, Naoki, Ingen, J. van, Zweijpfenning, S.M.H., Yim, Jae-Joon, Kwak, Nakwon, Dalcolmo, Margareth Pretti, Daley, Charles L., Eather, Geoffrey, Gayoso, Regina, Hasegawa, Naoki, Ingen, J. van, Zweijpfenning, S.M.H., and Yim, Jae-Joon

Abstract

Item does not contain fulltext

Published
2019

8. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad, Nafees, Ahuja, Shama D, Akkerman, Onno W, Alffenaar, Jan-Willem C, Anderson, Laura F, Baghaei, Parvaneh, Bang, Didi, Barry, Pennan M, Bastos, Mayara L, Behera, Digamber, Benedetti, Andrea, Bisson, Gregory P, Boeree, Martin J, Bonnet, Maryline, Brode, Sarah K, Brust, James CM, Cai, Ying, Caumes, Eric, Cegielski, J Peter, Centis, Rosella, Chan, Pei-Chun, Chan, Edward D, Chang, Kwok-Chiu, Charles, Macarthur, Cirule, Andra, Dalcolmo, Margareth Pretti, D'Ambrosio, Lia, de Vries, Gerard, Dheda, Keertan, Esmail, Aliasgar, Flood, Jennifer, Fox, Gregory J, Fréchet-Jachym, Mathilde, Fregona, Geisa, Gayoso, Regina, Gegia, Medea, Gler, Maria Tarcela, Gu, Sue, Guglielmetti, Lorenzo, Holtz, Timothy H, Hughes, Jennifer, Isaakidis, Petros, Jarlsberg, Leah, Kempker, Russell R, Keshavjee, Salmaan, Khan, Faiz Ahmad, Kipiani, Maia, Koenig, Serena P, Koh, Won-Jung, Kritski, Afranio, Kuksa, Liga, Kvasnovsky, Charlotte L, Kwak, Nakwon, Lan, Zhiyi, Lange, Christoph, Laniado-Laborín, Rafael, Lee, Myungsun, Leimane, Vaira, Leung, Chi-Chiu, Leung, Eric Chung-Ching, Li, Pei Zhi, Lowenthal, Phil, Maciel, Ethel L, Marks, Suzanne M, Mase, Sundari, Mbuagbaw, Lawrence, Migliori, Giovanni B, Milanov, Vladimir, Miller, Ann C, Mitnick, Carole D, Modongo, Chawangwa, Mohr, Erika, Monedero, Ignacio, Nahid, Payam, Ndjeka, Norbert, O'Donnell, Max R, Padayatchi, Nesri, Palmero, Domingo, Pape, Jean William, Podewils, Laura J, Reynolds, Ian, Riekstina, Vija, Robert, Jérôme, Rodriguez, Maria, Seaworth, Barbara, Seung, Kwonjune J, Schnippel, Kathryn, Shim, Tae Sun, Singla, Rupak, Smith, Sarah E, Sotgiu, Giovanni, Sukhbaatar, Ganzaya, Tabarsi, Payam, Tiberi, Simon, Trajman, Anete, Trieu, Lisa, Udwadia, Zarir F, van der Werf, Tjip S, and Veziris, Nicolas

Subjects
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Moxifloxacin, Clinical Trials and Supportive Activities, Antitubercular Agents, Levofloxacin, Clofazimine, Medical and Health Sciences, Rare Diseases, Drug Therapy, Recurrence, Kanamycin, Clinical Research, General & Internal Medicine, Humans, Tuberculosis, Treatment Failure, Capreomycin, Diarylquinolines, Amikacin, Lung, Prevention, Linezolid, Evaluation of treatments and therapeutic interventions, Pulmonary, Multidrug-Resistant, Orphan Drug, Good Health and Well Being, Carbapenems, 6.1 Pharmaceuticals, Combination, Antimicrobial Resistance, Infection, Fluoroquinolones
Abstract

BackgroundTreatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis.MethodsIn this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016. We also searched reference lists from all systematic reviews of treatment of multidrug-resistant tuberculosis published since 2009. To be eligible, studies had to report original results, with end of treatment outcomes (treatment completion [success], failure, or relapse) in cohorts of at least 25 adults (aged >18 years). We used anonymised individual patient data from eligible studies, provided by study investigators, regarding clinical characteristics, treatment, and outcomes. Using propensity score-matched generalised mixed effects logistic, or linear regression, we calculated adjusted odds ratios and adjusted risk differences for success or death during treatment, for specific drugs currently used to treat multidrug-resistant tuberculosis, as well as the number of drugs used and treatment duration.FindingsOf 12 030 patients from 25 countries in 50 studies, 7346 (61%) had treatment success, 1017 (8%) had failure or relapse, and 1729 (14%) died. Compared with failure or relapse, treatment success was positively associated with the use of linezolid (adjusted risk difference 0·15, 95% CI 0·11 to 0·18), levofloxacin (0·15, 0·13 to 0·18), carbapenems (0·14, 0·06 to 0·21), moxifloxacin (0·11, 0·08 to 0·14), bedaquiline (0·10, 0·05 to 0·14), and clofazimine (0·06, 0·01 to 0·10). There was a significant association between reduced mortality and use of linezolid (-0·20, -0·23 to -0·16), levofloxacin (-0·06, -0·09 to -0·04), moxifloxacin (-0·07, -0·10 to -0·04), or bedaquiline (-0·14, -0·19 to -0·10). Compared with regimens without any injectable drug, amikacin provided modest benefits, but kanamycin and capreomycin were associated with worse outcomes. The remaining drugs were associated with slight or no improvements in outcomes. Treatment outcomes were significantly worse for most drugs if they were used despite in-vitro resistance. The optimal number of effective drugs seemed to be five in the initial phase, and four in the continuation phase. In these adjusted analyses, heterogeneity, based on a simulated I2 method, was high for approximately half the estimates for specific drugs, although relatively low for number of drugs and durations analyses.InterpretationAlthough inferences are limited by the observational nature of these data, treatment outcomes were significantly better with use of linezolid, later generation fluoroquinolones, bedaquiline, clofazimine, and carbapenems for treatment of multidrug-resistant tuberculosis. These findings emphasise the need for trials to ascertain the optimal combination and duration of these drugs for treatment of this condition.FundingAmerican Thoracic Society, Canadian Institutes of Health Research, US Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of America.

Published
2018

10. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

Author

Borisov, Sergey, primary, Danila, Edvardas, additional, Maryandyshev, Andrei, additional, Dalcolmo, Margareth, additional, Miliauskas, Skaidrius, additional, Kuksa, Liga, additional, Manga, Selene, additional, Skrahina, Alena, additional, Diktanas, Saulius, additional, Codecasa, Luigi Ruffo, additional, Aleksa, Alena, additional, Bruchfeld, Judith, additional, Koleva, Antoniya, additional, Piubello, Alberto, additional, Udwadia, Zarir Farokh, additional, Akkerman, Onno W., additional, Belilovski, Evgeny, additional, Bernal, Enrique, additional, Boeree, Martin J., additional, Cadiñanos Loidi, Julen, additional, Cai, Qingshan, additional, Cebrian Gallardo, Jose Joaquín, additional, Dara, Masoud, additional, Davidavičienė, Edita, additional, Forsman, Lina Davies, additional, De Los Rios, Jorge, additional, Denholm, Justin, additional, Drakšienė, Jacinta, additional, Duarte, Raquel, additional, Elamin, Seifeldin Eltaeb, additional, Escobar Salinas, Nadia, additional, Ferrarese, Maurizio, additional, Filippov, Alexey, additional, Garcia, Ana, additional, García-García, José-María, additional, Gaudiesiute, Ieva, additional, Gavazova, Blagovesta, additional, Gayoso, Regina, additional, Gomez Rosso, Roscio, additional, Gruslys, Vygantas, additional, Gualano, Gina, additional, Hoefsloot, Wouter, additional, Jonsson, Jerker, additional, Khimova, Elena, additional, Kunst, Heinke, additional, Laniado-Laborín, Rafael, additional, Li, Yang, additional, Magis-Escurra, Cecile, additional, Manfrin, Vinicio, additional, Marchese, Valentina, additional, Martínez Robles, Elena, additional, Matteelli, Alberto, additional, Mazza-Stalder, Jesica, additional, Moschos, Charalampos, additional, Muñoz-Torrico, Marcela, additional, Mustafa Hamdan, Hamdan, additional, Nakčerienė, Birutė, additional, Nicod, Laurent, additional, Nieto Marcos, Magnolia, additional, Palmero, Domingo Juan, additional, Palmieri, Fabrizio, additional, Papavasileiou, Apostolos, additional, Payen, Marie-Christine, additional, Pontarelli, Agostina, additional, Quirós, Sarai, additional, Rendon, Adrian, additional, Saderi, Laura, additional, Šmite, Agnese, additional, Solovic, Ivan, additional, Souleymane, Mahamadou Bassirou, additional, Tadolini, Marina, additional, van den Boom, Martin, additional, Vescovo, Marisa, additional, Viggiani, Pietro, additional, Yedilbayev, Askar, additional, Zablockis, Rolandas, additional, Zhurkin, Dmitry, additional, Zignol, Matteo, additional, Visca, Dina, additional, Spanevello, Antonio, additional, Caminero, José A., additional, Alffenaar, Jan-Willem, additional, Tiberi, Simon, additional, Centis, Rosella, additional, D'Ambrosio, Lia, additional, Pontali, Emanuele, additional, Sotgiu, Giovanni, additional, and Migliori, Giovanni Battista, additional

Published
2019
Full Text
View/download PDF

11. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis

Author

Kwak, Nakwon, primary, Dalcolmo, Margareth Pretti, additional, Daley, Charles L., additional, Eather, Geoffrey, additional, Gayoso, Regina, additional, Hasegawa, Naoki, additional, Jhun, Byung Woo, additional, Koh, Won-Jung, additional, Namkoong, Ho, additional, Park, Jimyung, additional, Thomson, Rachel, additional, van Ingen, Jakko, additional, Zweijpfenning, Sanne M.H., additional, and Yim, Jae-Joon, additional

Published
2019
Full Text
View/download PDF

12. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Author

Ahmad, Nafees, primary, Ahuja, Shama D, additional, Akkerman, Onno W, additional, Alffenaar, Jan-Willem C, additional, Anderson, Laura F, additional, Baghaei, Parvaneh, additional, Bang, Didi, additional, Barry, Pennan M, additional, Bastos, Mayara L, additional, Behera, Digamber, additional, Benedetti, Andrea, additional, Bisson, Gregory P, additional, Boeree, Martin J, additional, Bonnet, Maryline, additional, Brode, Sarah K, additional, Brust, James C M, additional, Cai, Ying, additional, Caumes, Eric, additional, Cegielski, J Peter, additional, Centis, Rosella, additional, Chan, Pei-Chun, additional, Chan, Edward D, additional, Chang, Kwok-Chiu, additional, Charles, Macarthur, additional, Cirule, Andra, additional, Dalcolmo, Margareth Pretti, additional, D'Ambrosio, Lia, additional, de Vries, Gerard, additional, Dheda, Keertan, additional, Esmail, Aliasgar, additional, Flood, Jennifer, additional, Fox, Gregory J, additional, Fréchet-Jachym, Mathilde, additional, Fregona, Geisa, additional, Gayoso, Regina, additional, Gegia, Medea, additional, Gler, Maria Tarcela, additional, Gu, Sue, additional, Guglielmetti, Lorenzo, additional, Holtz, Timothy H, additional, Hughes, Jennifer, additional, Isaakidis, Petros, additional, Jarlsberg, Leah, additional, Kempker, Russell R, additional, Keshavjee, Salmaan, additional, Khan, Faiz Ahmad, additional, Kipiani, Maia, additional, Koenig, Serena P, additional, Koh, Won-Jung, additional, Kritski, Afranio, additional, Kuksa, Liga, additional, Kvasnovsky, Charlotte L, additional, Kwak, Nakwon, additional, Lan, Zhiyi, additional, Lange, Christoph, additional, Laniado-Laborín, Rafael, additional, Lee, Myungsun, additional, Leimane, Vaira, additional, Leung, Chi-Chiu, additional, Leung, Eric Chung-Ching, additional, Li, Pei Zhi, additional, Lowenthal, Phil, additional, Maciel, Ethel L, additional, Marks, Suzanne M, additional, Mase, Sundari, additional, Mbuagbaw, Lawrence, additional, Migliori, Giovanni B, additional, Milanov, Vladimir, additional, Miller, Ann C, additional, Mitnick, Carole D, additional, Modongo, Chawangwa, additional, Mohr, Erika, additional, Monedero, Ignacio, additional, Nahid, Payam, additional, Ndjeka, Norbert, additional, O'Donnell, Max R, additional, Padayatchi, Nesri, additional, Palmero, Domingo, additional, Pape, Jean William, additional, Podewils, Laura J, additional, Reynolds, Ian, additional, Riekstina, Vija, additional, Robert, Jérôme, additional, Rodriguez, Maria, additional, Seaworth, Barbara, additional, Seung, Kwonjune J, additional, Schnippel, Kathryn, additional, Shim, Tae Sun, additional, Singla, Rupak, additional, Smith, Sarah E, additional, Sotgiu, Giovanni, additional, Sukhbaatar, Ganzaya, additional, Tabarsi, Payam, additional, Tiberi, Simon, additional, Trajman, Anete, additional, Trieu, Lisa, additional, Udwadia, Zarir F, additional, van der Werf, Tjip S, additional, Veziris, Nicolas, additional, Viiklepp, Piret, additional, Vilbrun, Stalz Charles, additional, Walsh, Kathleen, additional, Westenhouse, Janice, additional, Yew, Wing-Wai, additional, Yim, Jae-Joon, additional, Zetola, Nicola M, additional, Zignol, Matteo, additional, and Menzies, Dick, additional

Published
2018
Full Text
View/download PDF

13. Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015

Author

Dalcolmo, Margareth, primary, Gayoso, Regina, additional, Sotgiu, Giovanni, additional, D'Ambrosio, Lia, additional, Rocha, Jorge Luiz, additional, Borga, Liamar, additional, Fandinho, Fatima, additional, Braga, Jose Ueleres, additional, Arakaki Sanchez, Denise, additional, Dockhorn, Fernanda, additional, Centis, Rosella, additional, and Migliori, Giovanni Battista, additional

Published
2017
Full Text
View/download PDF

14. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil

Author

Dalcolmo, Margareth, primary, Gayoso, Regina, additional, Sotgiu, Giovanni, additional, D'Ambrosio, Lia, additional, Rocha, Jorge L., additional, Borga, Liamar, additional, Fandinho, Fatima, additional, Braga, Jose U., additional, Galesi, Vera M.N., additional, Barreira, Draurio, additional, Sanchez, Denise A., additional, Dockhorn, Fernanda, additional, Centis, Rosella, additional, Caminero, Jose A., additional, and Migliori, Giovanni B., additional

Published
2017
Full Text
View/download PDF

15. M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis.

Author

Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, and Yim JJ

Subjects
Aged, Amikacin, Azithromycin, Clarithromycin, Databases, Factual, Female, Humans, Imipenem, Lung Diseases microbiology, Male, Microbial Sensitivity Tests, Middle Aged, Anti-Bacterial Agents therapeutic use, Lung Diseases drug therapy, Mycobacterium Infections, Nontuberculous drug therapy, Mycobacterium abscessus drug effects
Abstract

Treatment of Mycobacterium abscessus pulmonary disease (MAB-PD), caused by M. abscessus subsp. abscessus , M. abscessus subsp. massiliense or M. abscessus subsp. bolletii , is challenging.We conducted an individual patient data meta-analysis based on studies reporting treatment outcomes for MAB-PD to clarify treatment outcomes for MAB-PD and the impact of each drug on treatment outcomes. Treatment success was defined as culture conversion for ≥12 months while on treatment or sustained culture conversion without relapse until the end of treatment.Among 14 eligible studies, datasets from eight studies were provided and a total of 303 patients with MAB-PD were included in the analysis. The treatment success rate across all patients with MAB-PD was 45.6%. The specific treatment success rates were 33.0% for M. abscessus subsp. abscessus and 56.7% for M. abscessus subsp. massiliense For MAB-PD overall, the use of imipenem was associated with treatment success (adjusted odds ratio (aOR) 2.65, 95% CI 1.36-5.10). For patients with M. abscessus subsp. abscessus , the use of azithromycin (aOR 3.29, 95% CI 1.26-8.62), parenteral amikacin (aOR 1.44, 95% CI 1.05-1.99) or imipenem (aOR 7.96, 95% CI 1.52-41.6) was related to treatment success. For patients with  M. abscessus subsp. massiliense , the choice among these drugs was not associated with treatment outcomes.Treatment outcomes for MAB-PD are unsatisfactory. The use of azithromycin, amikacin or imipenem was associated with better outcomes for patients with M. abscessus subsp. abscessus ., Competing Interests: Conflict of interest: N. Kwak has nothing to disclose. Conflict of interest: M.P. Dalcolmo has nothing to disclose. Conflict of interest: C.L. Daley reports grants and personal fees from Insmed, and personal fees from Horizon, Spero and Johnson and Johnson, outside the submitted work. Conflict of interest: G. Eather has nothing to disclose. Conflict of interest: R. Gayoso has nothing to disclose. Conflict of interest: N. Hasegawa reports grants and personal fees from Insmed Inc., during the conduct of the study; grants from Nikon Corporation, Taisho-Toyama Pharmaceutical Co., Ltd, Eisai Co., Ltd, Daiichi Sankyo Co., Ltd, MSD KK a subsidiary of Merck & Co. Inc., Sumitomo Dainippon Pharma Co., Ltd, Pfizer Inc., Astellas Pharma Inc., Cepheid Inc., Precision System Science Co., Ltd, and Medical and Biological Laboratories Co., Ltd, outside the submitted work. Conflict of interest: B.W. Jhun has nothing to disclose. Conflict of interest: W-J. Koh has received a consultation fee from Insmed Inc. for the Insmed advisory board meeting, not associated with the submitted work. Conflict of interest: H. Namkoong has nothing to disclose. Conflict of interest: J. Park has nothing to disclose. Conflict of interest: R. Thomson reports personal fees for advisory board work from Insmed and Savara, and personal fees for CME talks from Menarini and AstraZeneca, outside the submitted work. Conflict of interest: J. van Ingen reports personal fees for advisory board membership from Insmed, Spero Therapeutics and Johnson & Johnson, during the conduct of the study. Conflict of interest: S.M.H. Zweijpfenning reports personal fees and nonfinancial support from Insmed and Novartis outside the submitted work. Conflict of interest: J-J. Yim has nothing to disclose., (Copyright ©ERS 2019.)

Published
2019
Full Text
View/download PDF

16. Uptake of governmental social protection and financial hardship during drug-resistant tuberculosis treatment in Rio de Janeiro, Brazil.

Author

Rudgard WE, das Chagas NS, Gayoso R, Barreto ML, Boccia D, Smeeth L, Rodrigues LC, Lönnroth K, Williamson E, and Maciel ELN

Subjects
Adult, Brazil epidemiology, Female, Health Services Accessibility, Humans, Male, National Health Programs, Surveys and Questionnaires, Universal Health Insurance, Communicable Disease Control legislation & jurisprudence, Health Policy, Infectious Disease Medicine legislation & jurisprudence, Poverty, Tuberculosis, Multidrug-Resistant economics, Tuberculosis, Multidrug-Resistant therapy
Abstract

Competing Interests: Conflict of interest: W.E. Rudgard reports grants from Medical Research Council (MRC), during the conduct of the study. Conflict of interest: L. Smeeth reports a fellowship grant from the Wellcome Trust, during the conduct of the study; grants from the Wellcome Trust, the MRC and the National Institute for Health Research (NIHR) outside the submitted work; and grants and personal fees from GSK, for advisory work unrelated to this report or its content. He is also a Trustee of the British Heart Foundation.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results